At a glance
ClinicalIndex Comparison Record- ✓Prostate adenocarcinoma treated with radical prostatectomy
- ✓Tumor stage pT2-4, R0-1, pN0, or cN0, cNx with Gleason score
- ✓No lymph node or distant metastases on recent PSMA-PET scan (<60 days)
- ✓PSA progression: two consecutive rises with final PSA >0.1 ng/mL or three consecutive rises, first measured ≥6 weeks post-prostatectomy
- ✕Prior pelvic irradiation
- ✕Prior or concurrent hormonal therapy or chemohormonal therapy
- ✕Prior orchiectomy
- ✕Previous or concurrent active invasive cancers other than superficial non-melanoma skin cancers
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy of Biochemical Failure After Radical Prostatectomy for Prostate Cancer
In Brief
A Phase 3 clinical trial evaluating Conventional sEBRT and Hypofractionated sEBRT for Prostate Cancer and Cancer Recurrence. Currently recruiting, targeting 538 participants across 13 sites.
Detailed Summary
After radical prostatectomy approximately 15-40% of men develop a biochemical recurrence (BR) within 5 years. The standard treatment of post-prostatectomy BR is salvage external beam radiation therapy (sEBRT). sEBRT can provide long-term disease control; with 5 year biochemical progression-free survival (bPFS) up to 60% and with most treatment failures in the first 2 years after sEBRT. The main goal of this project is to investigate whether the oncologic outcome in patients with post-prostatectomy recurrent PCa can be improved, by increasing the biological effective radiation dose using a hypofractionated schedule of 20 x 3 = 60 Gy. The study is designed as a prospective open phase III randomized multicenter trial. All patients with biochemical recurrence with a PSA \< 1.0 ng/ml after radical prostatectomy for prostate cancer without evidence of lymph nodes or distance metastases will be included. PSA progression after prostatectomy defined as two consecutive rises with the final PSA \> 0.1 ng/mL or three consecutive rises will be included. All eligible patients will be randomized to one of the following two treatment arms: Arm 1 = Conventional sEBRT to apply a total dose of 70 Gy in 35 daily fractions of 2 Gy during 7 weeks. Arm 2 = Hypofractionated sEBRT to apply a total dose of 60 Gy in 20 fractions of 3 Gy during 4 weeks. The primary endpoint will be the 5-year progression-free survival (PFS) after treatment.
Study Details
Timeline
Interventions
A total dose of70 Gy in 35 daily fractions of 2 Gy during 7 weeks
A total dose of 60 Gy in 20 daily fractions of 3 Gy during 4 weeks